Agenus | AGEN - Ebitda


Agenus reported $-10.11M in EBITDA for its fiscal quarter ending in March of 2025.





Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Agenus USD -10.11M 19.02M Mar/2025
Amgen USD 5.14B 775M Dec/2025
AstraZeneca USD 5.23B 272M Sep/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Celldex Therapeutics USD -86.34M 13.54M Dec/2025
CSL USD 3.13B 1.17B Dec/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
Incyte USD 414.5M 92.42M Dec/2025
Intrexon USD -24.7M 2.92M Jun/2024
J&J USD 9.52B 389M Sep/2025
Jiangsu Hengrui CNY 2.98B 890.87M Jun/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
MacroGenics USD 21.95M 55.39M Sep/2025
Merck EUR 1.44B 263M Dec/2025
Merck USD 8.39B 1.97B Sep/2025
Northwest Biotherapeutics USD -13.41M 232K Sep/2023
Novartis USD 4.77B 1.11B Dec/2025
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 6.08B 351M Sep/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Veracyte USD 42.31M 2.58M Dec/2025